CTSO — Cytosorbents Corporation

Cytosorbents (CTSO) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue was $8.9 million, a 2% increase year-over-year but down 7% on a constant currency basis.
• International Direct Sales: Grew 13% year-over-year, while sales in Germany declined.
• Gross Margin: 69%, down from 71% year-over-year, attributed to intentional production slowdowns to manage inventory.
• Operating Expenses: Reduced to $9.2 million from $10.1 million a year ago, reflecting cost-cutting measures.
• Operating Loss: Improved to $3 million, a 22% reduction from $3.9 million in the prior year.
• Net Loss: Increased to $5.1 million ($0.08 per share) from $1.5 million ($0.02 per share) due to noncash foreign currency impacts.
• Adjusted Net Loss: Improved to $3.4 million ($0.05 per share) from $3.7 million ($0.06 per share).
• Cash Position: Approximately $6.4 million at the end of Q1, down from $7.8 million at year-end.

2. Strategic Updates and Business Highlights

• Product Development: CytoSorb is approved in the EU for various indications, while DrugSorb-ATR is still investigational. The company is focusing on expanding its clinical applications and improving physician utilization strategies.
• Market Expansion: The international core CytoSorb business is growing, with over 300,000 devices used in more than 70 countries. The company is also exploring opportunities in the Middle East despite geopolitical challenges.
• Operational Improvements: The company is refining its sales strategy in Germany and plans to selectively rebuild its sales force to enhance market coverage.
• Clinical Evidence: New data from the STAR-T trial supports the safety and efficacy of DrugSorb-ATR in reducing bleeding during cardiac surgery.

3. Forward Guidance and Outlook

• Regulatory Pathway: The company is preparing for a new de novo submission for DrugSorb-ATR, expected to be filed in late 2026 or early 2027. They aim to achieve operating cash flow breakeven in the second half of 2026.
• Growth Expectations: Management remains optimistic about stabilizing and growing the German market, while international markets are showing promising growth.

4. Bad News, Challenges, or Points of Concern

• Geopolitical Risks: Delays in distributor orders in the Middle East due to the U.S.-Iran conflict impacted expected revenue by approximately $0.5 million.
• Sales Decline in Germany: While there are signs of improvement, sales in Germany remain a concern, and the company is in the process of restructuring its sales force.
• Increased Net Loss: The significant increase in net loss is concerning, primarily driven by noncash foreign currency impacts.

5. Notable Q&A Insights

• Regulatory Clarifications: The FDA has requested additional mechanistic data for DrugSorb-ATR, which will not require a clinical trial but will involve non-clinical studies. The specifics of these studies are still being finalized.
• Expansion Plans: The company is optimistic about the potential for expanding DrugSorb-ATR's label to include direct oral anticoagulants (DOACs), with plans to submit a pre-submission request to the FDA shortly.
• Middle East Market: Management expressed confidence in recovering delayed orders once geopolitical stability returns, highlighting ongoing interest from physicians in the region.

Overall, Cytosorbents is navigating a challenging environment but is making strides in operational efficiency and clinical validation, with a focus on future growth opportunities.